← Back to Clinical Trials
Recruiting NCT05704582

NCT05704582 RCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05704582
Status Recruiting
Phase
Sponsor Ciusss de L'Est de l'Île de Montréal
Condition Psychotic Disorders
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2023-02-01
Primary Completion 2027-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Avatar InterventionAddiction supportive intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2023-02-01 with a primary completion date of 2027-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to conduct a single-blind randomized controlled trial to verify whether the Avatar Intervention has greater efficacy over supportive intervention to reduce cannabis use in patients with psychotic disorders.

Eligibility Criteria

Inclusion Criteria: * Males or females over 18 years of age who meet the DSM-5 criteria for CUD (≥4 criteria) ; * Patients will meet the DSM-5 criteria for schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic symptoms. Diagnoses will be established with the Structured Interview for DSM-5 (SCID-5). Exclusion Criteria: * Current SUD for a substance other than cannabis ; * Ongoing pharmacological or psychological treatment for CUD ; * Ongoing detoxification for cannabis withdrawal ; * Presence of neurological disorders ; * Presence of a severe and unstable physical illness ; * Inability to provide consent.

Contact & Investigator

Central Contact

Alexandre Dumais, MD, PhD

✉ contact@avatar-intervention.ca

📞 514-251-4000

Principal Investigator

Alexandre Dumais, MD, PhD

PRINCIPAL INVESTIGATOR

University of Montreal, Institut universitaire en santé mentale de Montréal

Frequently Asked Questions

Who can join the NCT05704582 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Psychotic Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05704582 currently recruiting?

Yes, NCT05704582 is actively recruiting participants. Contact the research team at contact@avatar-intervention.ca for enrollment information.

Where is the NCT05704582 trial being conducted?

This trial is being conducted at Montreal, Canada.

Who is sponsoring the NCT05704582 clinical trial?

NCT05704582 is sponsored by Ciusss de L'Est de l'Île de Montréal. The principal investigator is Alexandre Dumais, MD, PhD at University of Montreal, Institut universitaire en santé mentale de Montréal. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology